195.09

0.48% -0.94

After Hours: 195.09

Axsome Therapeutics Inc (AXSM)

Overview News Price History Option Chain Financials Why AXSM Down? Discussions Forecast

Axsome Therapeutics Inc stock is traded at $195.09, with a volume of 838.17K. It is down -0.48% in the last 24 hours and down -5.06% over the past month. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Previous Close:

$196.03

Open:

$197.68

24h Volume:

838.17K

Relative Volume:

1.03

Market Cap:

$10.22B

Revenue:

$708.24M

Net Income/Loss:

$-188.30M

P/E Ratio:

-52.17

EPS:

-3.7392

Net Cash Flow:

$-70.99M

1W Performance:

-6.11%

1M Performance:

-5.06%

6M Performance:

+20.59%

1Y Performance:

+68.17%

1-Day Range:

$194.35

$201.42

1-Week Range:

$189.05

$210.85

52-Week Range:

$115.72

$260.19

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name

Axsome Therapeutics Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(212) 332-3241

Address

ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK

Employee

925

Twitter

Next Earnings Date

2026-11-02

Latest SEC Filings

AXSM's Discussions on Twitter

Compare AXSM vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AXSM Axsome Therapeutics Inc	195.09	10.22B	708.24M	-188.30M	-70.99M	-3.7392
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Wolfe Research	Outperform
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-01-25	Initiated	B. Riley Securities	Buy
Sep-03-25	Resumed	Wells Fargo	Overweight
Jul-03-25	Resumed	Morgan Stanley	Overweight
Jun-03-25	Initiated	Oppenheimer	Outperform
Apr-07-25	Initiated	Jefferies	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-31-24	Reiterated	Mizuho	Outperform
Sep-03-24	Initiated	Wells Fargo	Overweight
Aug-06-24	Upgrade	BofA Securities	Neutral → Buy
Jul-22-24	Initiated	Needham	Buy
Apr-29-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-19-24	Initiated	Robert W. Baird	Outperform
Feb-06-24	Initiated	UBS	Buy
Jan-25-24	Initiated	RBC Capital Mkts	Outperform
Dec-13-23	Initiated	Citigroup	Buy
Aug-08-23	Upgrade	BofA Securities	Underperform → Neutral
Jan-05-23	Initiated	Piper Sandler	Neutral
Nov-01-22	Initiated	Loop Capital	Buy
Sep-07-22	Resumed	Mizuho	Buy
Aug-10-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-10-21	Initiated	Berenberg	Buy
Jan-08-21	Initiated	Jefferies	Buy
Dec-16-20	Initiated	Mizuho	Buy
Sep-29-20	Initiated	BofA Securities	Underperform
Sep-10-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Reiterated	H.C. Wainwright	Buy
Apr-14-20	Initiated	Cowen	Outperform
Dec-30-19	Reiterated	H.C. Wainwright	Buy
Dec-17-19	Reiterated	H.C. Wainwright	Buy
Dec-16-19	Reiterated	Guggenheim	Buy
Oct-16-19	Initiated	Guggenheim	Buy
Sep-18-19	Initiated	William Blair	Outperform
May-28-19	Initiated	SunTrust	Buy
May-23-19	Reiterated	H.C. Wainwright	Buy
Apr-08-19	Initiated	SVB Leerink	Outperform
Mar-15-19	Reiterated	H.C. Wainwright	Buy
Oct-03-16	Resumed	Brean Capital	Buy
Dec-15-15	Initiated	Cantor Fitzgerald	Buy
Dec-14-15	Initiated	Ladenburg Thalmann	Buy

View All

Axsome Therapeutics Inc Stock (AXSM) Latest News

01:41 AM

Axsome Therapeutics Is Maintained at Equal-Weight by Morgan Stanley - Moomoo

01:41 AM

Sep 25, 2026

AXSM Maintains Rating by Morgan Stanley -- Price Target Lowered to $247 - gurufocus.com

Sep 25, 2026

H.C. Wainwright reiterates Axsome stock Buy rating at $290 target By Investing.com - Investing.com Canada

Sep 25, 2026

AXSOME THERAPEUTICS, INC. : TRUIST SECURITIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $285 VS $200 - webull.com

Sep 25, 2026

Sep 24, 2026

$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today - Benzinga

Sep 24, 2026

AXSM Stock Price and Chart — NASDAQ:AXSM - TradingView

Sep 24, 2026

Sep 23, 2026

10 Health Care Stocks Whale Activity In Today’s Session - Benzinga

Sep 23, 2026

Truist Securities maintains Buy rating on Axsome Therapeutics, $285 price target - TradingView

Sep 23, 2026

Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - marketscreener.com

Sep 23, 2026

Truist initiates Axsome stock coverage with buy rating on growth By Investing.com - Investing.com Nigeria

Sep 23, 2026

Truist initiates Axsome stock coverage with buy rating on growth - Investing.com

Sep 23, 2026

Sep 22, 2026

Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits

Sep 22, 2026

Sep 21, 2026

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day - The Manila Times

Sep 21, 2026

Axsome Therapeutics Announces Results of the Shared Goals - GlobeNewswire

Sep 21, 2026